;%20}%20%3c/style%3e%3clinearGradient%20id='linear-gradient'%20x1='1.11'%20y1='1589.13'%20x2='229.47'%20y2='1589.13'%20gradientTransform='translate(0%201706.13)%20scale(1%20-1)'%20gradientUnits='userSpaceOnUse'%3e%3cstop%20offset='.54'%20stop-color='%23000'%20stop-opacity='0'/%3e%3cstop%20offset='1'%20stop-color='%23000'/%3e%3c/linearGradient%3e%3c/defs%3e%3crect%20class='cls-1'%20x='1.11'%20y='.78'%20width='339.79'%20height='232.43'/%3e%3cpath%20d='M37.18,123.61h-15.78l-4.95,12.17h-2.67l15.61-38.18,15.4,38.18h-2.67l-4.95-12.17h0ZM36.3,121.39l-6.95-17.56-7.05,17.56h14.01,0Z'/%3e%3cpath%20d='M68.8,118h15.56c0,3.39-.73,8.28-3.78,12.17-3.28,4.17-8.28,6.22-13.94,6.22-10.89,0-19.17-8-19.17-19.06s8.56-19.12,19.34-19.12c5.22,0,8.73,1.77,11.61,4,1.56,1.22,2.95,2.55,4.45,4.67l-1.94,1.56c-1.06-1.77-2.55-3.28-3.56-4.11-2.33-1.94-6-3.89-10.61-3.89-9.5,0-16.72,7.56-16.72,17s7,16.72,16.56,16.72c6.34,0,10.89-3.23,12.9-6.28,1.44-2.22,2.33-5.28,2.45-7.67h-13.11v-2.22l-.02.02Z'/%3e%3cpath%20d='M110.14,100.94h-15.33v13.45h15v2.22h-15v16.95h15.33v2.22h-17.78v-37.07h17.78v2.22Z'/%3e%3cpath%20d='M131.09,98.71h8.11c6.44,0,10.23,3.72,10.23,9.28,0,4-1.89,6.61-4.34,8.11,4.83.78,7.67,4.5,7.67,9.28,0,6.5-4.78,10.4-11.51,10.4h-10.17v-37.07h0ZM133.53,115.5h5.89c1.89,0,3.44-.22,5.05-1.56,1.5-1.22,2.45-3.11,2.45-5.66,0-2.95-1.28-4.78-2.5-5.78-1.84-1.44-4.22-1.56-6.17-1.56h-4.72v14.56ZM133.53,133.56h6.23c2.5,0,5.56,0,8.06-2.22,2-1.77,2.39-3.94,2.39-5.66,0-3.33-1.17-5.61-3.94-6.89-1-.45-2.83-1.06-6.95-1.06h-5.78v15.84h0Z'/%3e%3cpath%20d='M179.93,123.61h-15.78l-4.95,12.17h-2.67l15.61-38.18,15.4,38.18h-2.67l-4.95-12.17h0ZM179.04,121.39l-6.95-17.56-7.05,17.56h14.01,0Z'/%3e%3cpath%20d='M221.88,106.27c-3.16-3.72-7.72-5.83-12.5-5.83-9.5,0-16.62,7.61-16.62,17,0,11,9.17,16.72,16.67,16.72,3.72,0,8.67-1.5,12.45-5.61v3.23c-3.78,3.33-8.33,4.61-12.34,4.61-11.11,0-19.34-8.72-19.34-19.06s8.56-19.12,19.22-19.12c7.05,0,11.34,3.78,12.45,4.83v3.23h0Z'/%3e%3cpath%20d='M235.1,116.44l17.95-17.73h-3.23l-17.5,17.45v-.56c-.36.69-.93,1.27-1.71,1.6.05.42.02.84-.06,1.26.72.03,1.33.22,1.82.54l.94-.89,17.45,17.67h3.33l-19.01-19.34h0Z'/%3e%3cpath%20d='M302.5,106.27c-3.16-3.72-7.72-5.83-12.5-5.83-9.5,0-16.62,7.61-16.62,17,0,11,9.17,16.72,16.67,16.72,3.72,0,8.67-1.5,12.45-5.61v3.23c-3.78,3.33-8.33,4.61-12.34,4.61-11.11,0-19.34-8.72-19.34-19.06s8.56-19.12,19.22-19.12c7.05,0,11.34,3.78,12.45,4.83v3.23h0Z'/%3e%3cpath%20d='M330.67,124.5c0,6.72-5.17,11.89-11.89,11.89s-11.89-5.17-11.89-11.89,5.17-11.89,11.89-11.89,11.89,5.17,11.89,11.89ZM328.34,124.5c0-5.5-4.11-9.78-9.55-9.78s-9.55,4.28-9.55,9.78,4.11,9.78,9.55,9.78,9.55-4.28,9.55-9.78Z'/%3e%3cpath%20d='M338.84,132.05c1.17,0,2.05.89,2.05,2.05s-.89,2.05-2.05,2.05-2.05-.89-2.05-2.05.89-2.05,2.05-2.05Z'/%3e%3cpath%20class='cls-2'%20d='M117.32,233.21C53.24,233.21,1.11,181.07,1.11,117S53.24.78,117.32.78c51.99,0,98.03,34.94,111.97,84.97l-2.23.62C213.4,37.34,168.28,3.1,117.32,3.1,54.52,3.1,3.42,54.19,3.42,117s51.1,113.9,113.9,113.9c51.27,0,96.47-34.52,109.92-83.93l2.23.61c-13.71,50.42-59.83,85.65-112.15,85.65h0Z'/%3e%3cpath%20d='M230.86,136.5l-2.28-.39c2.11-12.49,2.14-25.18.08-37.71l2.28-.37c2.09,12.79,2.06,25.73-.08,38.47Z'/%3e%3c/svg%3e)
Ezogelin Oflazoğlu-Gruyters, Ph.D.
Board Member, Vivosel
VP, Head of External R&D & Strategic Alliances at AstraZeneca. 25+ years in biologics and immuno-oncology. Key role in developing ADCETRIS™, KEYTRUDA®, VIDAZA®, and LUMOXITI™.
Biography
Dr. Ezogelin Oflazoğlu-Gruyters is a highly accomplished pharmaceutical executive serving as VP and Head of External R&D & Strategic Alliances at AstraZeneca. With over 25 years of experience in biologics and immuno-oncology, she has been instrumental in the development of some of the most important cancer therapies of our time.
Her contributions to drug development include key roles in bringing ADCETRIS™, KEYTRUDA®, VIDAZA®, and LUMOXITI™ to market—therapies that have transformed the treatment landscape for thousands of cancer patients worldwide.
As a Board Member at Vivosel, Dr. Oflazoğlu-Gruyters provides invaluable expertise in biologics development, regulatory strategy, and strategic partnerships. Her deep understanding of the pharmaceutical industry's requirements helps ensure Vivosel's therapies are developed to the highest standards.
Background
- •Ph.D., Immunology/Cancer Biology
- •Post-doctoral research in Biologics Development
Key Achievements
- •VP, Head of External R&D & Strategic Alliances at AstraZeneca
- •Key role in developing ADCETRIS™ (antibody-drug conjugate)
- •Key role in developing KEYTRUDA® (pembrolizumab, anti-PD-1)
- •Key role in developing VIDAZA® (azacitidine)
- •Key role in developing LUMOXITI™ (moxetumomab pasudotox)
- •25+ years in biologics and immuno-oncology
Other Team Members
Nathalie Helm, MD
Chief Medical Officer, Age Back Co.
Estelle Nordenfalk
CEO, Age Back Co. Stockholm
Jorn Elferink
Co-Founder, Age Back Co. B.V.
Cem Arel
Board Member, Vivosel | Founder & CEO, Age Back Co.
Metin Kurtoğlu, M.D., Ph.D.
Co-founder, Vivosel
Utku Ateş, M.D., Ph.D.
Co-founder, Vivosel
Mehmet Levent Selamoğlu
Board Member, Vivosel
Ulrika Holm
Event Manager / Sales
Jacqueline Lindholm Nordh
Club Director Stockholm
Annika Stampes
Safety Manager – Hyperbaric Oxygen Chamber
Krippe Smith
Resilience/Recovery Coordination
Kadir Devrim Demirel, MD
Chief Medical Officer, Ideal of MeD